Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stiripentol Suspension vs Capsule Bioavailability
NCT07176832Phase 1Completed
- Sponsor
- Biocodex
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of stiripentol in Dravet syndrome (2 arms), sponsored by Biocodex. Primary endpoints: Relative bioavailability of stiripentol oral suspension vs capsule (Cmax) at 36 hours, Relative bioavailability of stiripentol oral suspension vs capsule (AUC0-t) at 36 hours and 1 more. Started Jun 2025; status: completed.
02
Drugs
stiripentol
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT07176832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176832.